Armie Margaret Lee is a reporter covering private equity. Previously, she was at InvestmentWires, an online media company that focuses on the mutual fund and 401(k) industries. She has also covered real estate and banking for Miami Today and technology for Manila Times in the Philippines.
Recent Articles By The Author
Mesoblast Soars on Stem-Cell Treatment Data
The Australian company unveiled data from a study evaluating a potential treatment for children with steroid refractory acute Graft Versus Host Disease.
AT&T-Time Warner Ruling Could Usher in More Healthcare Deals
On the heels of the landmark antitrust decision, Bain's Kara Murphy expects to see more healthcare transactions.
PTC Shares Skyrocket on Positive Data for Spinal Muscular Atrophy Drug
Updated interim data from a study of risdiplam were presented June 16 at the 22nd Annual SMA Researcher Meeting.
Mylan Slumps in After-Hours Trading on Generic Advair Update
The drugmaker says the FDA will issue a complete response letter on June 27.
AT&T-Time Warner Ruling a Positive for Cigna-Express Scripts, CVS-Aetna Deals
The ruling has a positive read-across for Cigna's pending acquisition of Express Scripts and CVS' deal for Aetna, according to Leerink's Ana Gupte.
Stryker Says Not in Talks to Buy Boston Scientific
The medical device firm issues an 8-K filing on the heels of a media report earlier this week that said it recently made a takeover approach to Boston Scientific.
KKR Buying Envision Healthcare for $9.9 Billion
The deal comes nearly two months after Envision completed the sale of its medical transportation unit to KKR-backed Air Medical Group Holdings.
Merck Higher on Lung Cancer Data
The drugmaker's presentations at ASCO's annual meeting included data on Keynote-407, which Credit Suisse analyst Vamil Divan described as a 'clear positive.'
Allergan Says It's Looking to Sell Two of Its Units, But Not at Fire-Sale Prices
The Dublin-based drugmaker has wrapped up a strategic review of all its businesses, but says it's not pursuing a fire sale of its assets.
Celgene Shares Rise on Plans to Increase Stock Buybacks
The Summit, N.J.-based biotech firm also plans to enter into an accelerated share repurchase program to buy back $2 billion of stock.